Shipra Gandhi1, Manu Pandey1, Nischala Ammannagari1, Chong Wang2, Mark J Bucsek3, Lamya Hamad4,5, Elizabeth Repasky3, Marc S Ernstoff1,4. 1. Department of Medicine, Roswell Park Comprehensive Cancer Center, Elm & Carlton Streets, Buffalo, NY 14263, USA. 2. Department of Biostatistics, Roswell Park Comprehensive Cancer Center, Elm & Carlton Streets, Buffalo, NY 14263, USA. 3. Department of Immunology & Cell Stress & Biophysical Therapies Program, Elm & Carlton Streets, Buffalo, NY 14263, USA. 4. Melanoma Program, Roswell Park Comprehensive Cancer Center, Elm & Carlton Streets, Buffalo, NY 14263, USA. 5. Clinical Pharmacy Service, Roswell Park Comprehensive Cancer Center, Elm & Carlton Streets, Buffalo, NY 14263, USA.
Abstract
Aim: Patients receiving checkpoint inhibitors (CPI) are frequently on other medications for co-morbidities. We explored the impact of concomitant medication use on outcomes. Materials & methods: 210 metastatic cancer patients on CPI were identified and association between concomitant medication use and immune-related adverse events with clinical outcomes was determined. Results: Aspirin, metformin, β-blockers and statins were not shown to have any statistically significant difference on clinical benefit. 26.3% patients with clinical benefit developed rash versus 11.8% without clinical benefit (p < 0.05) on multivariate analysis. Conclusion: Use of common prescription and nonprescription medications in patients with multiple co-morbidities appears safe and does not have an adverse effect on CPI efficacy. The presence of rash predicted for a better response.
Aim: Patients receiving checkpoint inhibitors (CPI) are frequently on other medications for co-morbidities. We explored the impact of concomitant medication use on outcomes. Materials & methods: 210 metastatic cancerpatients on CPI were identified and association between concomitant medication use and immune-related adverse events with clinical outcomes was determined. Results:Aspirin, metformin, β-blockers and statins were not shown to have any statistically significant difference on clinical benefit. 26.3% patients with clinical benefit developed rash versus 11.8% without clinical benefit (p < 0.05) on multivariate analysis. Conclusion: Use of common prescription and nonprescription medications in patients with multiple co-morbidities appears safe and does not have an adverse effect on CPI efficacy. The presence of rash predicted for a better response.
Authors: Arnoud J Templeton; Olga Ace; Mairéad G McNamara; Mustafa Al-Mubarak; Francisco E Vera-Badillo; Thomas Hermanns; Boštjan Seruga; Alberto Ocaña; Ian F Tannock; Eitan Amir Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-05-03 Impact factor: 4.254
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Olivier Boutaud; I Romina Sosa; Taneem Amin; Denise Oram; David Adler; Hyun S Hwang; Brenda C Crews; Ginger Milne; Bradford K Harris; Megan Hoeksema; Bjorn C Knollmann; Philip E Lammers; Lawrence J Marnett; Pierre P Massion; John A Oates Journal: Cancer Prev Res (Phila) Date: 2016-08-23
Authors: Sean Hammond; Anna Olsson-Brown; Sophie Grice; Andrew Gibson; Joshua Gardner; Jose Luis Castrejón-Flores; Carol Jolly; Benjamin Alexis Fisher; Neil Steven; Catherine Betts; Munir Pirmohamed; Xiaoli Meng; Dean John Naisbitt Journal: Toxicol Sci Date: 2022-02-28 Impact factor: 4.849
Authors: Shipra Gandhi; Manu R Pandey; Elizabeth A Repasky; Marc S Ernstoff; Kristopher Attwood; Wenyan Ji; Agnieszka K Witkiewicz; Erik S Knudsen; Cheryl Allen; Joseph D Tario; Paul K Wallace; Carlos D Cedeno; Maria Levis; Suzanne Stack; Pauline Funchain; Joseph J Drabick; Mark J Bucsek; Igor Puzanov; Hemn Mohammadpour Journal: Clin Cancer Res Date: 2020-10-30 Impact factor: 13.801
Authors: Alessio Cortellini; Marco Tucci; Vincenzo Adamo; Luigia Stefania Stucci; Alessandro Russo; Enrica Teresa Tanda; Francesco Spagnolo; Francesca Rastelli; Renato Bisonni; Daniele Santini; Marco Russano; Cecilia Anesi; Raffaele Giusti; Marco Filetti; Paolo Marchetti; Andrea Botticelli; Alain Gelibter; Mario Alberto Occhipinti; Riccardo Marconcini; Maria Giuseppa Vitale; Linda Nicolardi; Rita Chiari; Claudia Bareggi; Olga Nigro; Alessandro Tuzi; Michele De Tursi; Nicola Petragnani; Laura Pala; Sergio Bracarda; Serena Macrini; Alessandro Inno; Federica Zoratto; Enzo Veltri; Barbara Di Cocco; Domenico Mallardo; Maria Grazia Vitale; David James Pinato; Giampiero Porzio; Corrado Ficorella; Paolo Antonio Ascierto Journal: J Immunother Cancer Date: 2020-11 Impact factor: 13.751